Pomerantz Law Firm Investigates Syndax Pharmaceuticals Following Failed Phase 2 Clinical Trial
Pomerantz LLP has launched an investigation into Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) to determine if the company or its executives engaged in securities fraud or unlawful business practices. The probe follows a significant clinical setback regarding the company's drug candidate, axatilimab. On October 12, 2026, Syndax announced that its MAXPIRe Phase 2 trial for axatilimab in treating idiopathic pulmonary fibrosis (IPF) failed to meet its primary endpoint. The failure was measured by the annualized rate of decline in forced vital capacity (FVC). Following this announcement, SNDX shares dropped 2.59% to close at $16.55 per share.
Tickers: $SNDX
Topics: class action lawsuit clinical trial failure investor protection securities fraud investigation
Read the full article at PR Newswire
Part of the story Pomerantz Law Firm Investigates EyePoint, Inc. Following Clinical Trial Failures (9 articles)